Because of T315I is well-recognized as a clinical significant point mutation that contributes to imatinib resistant in CML and it was predominantly observed in this study (57% of all mutated cases), we classified the treated patients into 4 main groups including patients without BCR-ABL1 TKD mutation, T315I mutation, compound/polyclonal mutations with T315I, and other TKD mutations (such as E255K, F317L, F359V/I, and F486S). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.